Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Here's Why You Should Add PODD Stock to Your Portfolio Now
Insulet stays on investors' radar owing to its solid progress with Omnipod 5 and strong solvency position.
PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU
Insulet announces the launch of Omnipod 5 in five more countries in Europe, Italy, Denmark, Finland, Norway and Sweden.
Heavy Interest in Insulet's Insulin Delivery Device
Sales are surging for Insulet Corporation (PODD).
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Continue to Retain Insulet Stock in Your Portfolio Now?
PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.
Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case
Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade secrets related to insulin pumps, according to a verdict made public in Massachusetts federal court on Thursday.
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US
Insulet's Omnipod 5 System is now compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.
Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
Insulet's stock has surged over 50% in six months due to strong Q3 earnings and expanded market potential with Omnipod 5's approval for Type 2 diabetes. Despite impressive growth, high market expectations and potential competition from giants like Medtronic and Abbott pose significant risks to Insulet's future performance. The company's financials are robust, with rising revenues, margins, and a strong cash position, but the stock's high valuation demands continued exceptional growth.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
PODD Stock Gains on Q3 Earnings and Revenue Beat, '24 Sales View Up
Insulet's third-quarter performance benefits from the continued high demand for Omnipod 5.
